Quick note: Monday's issue never made it to your inbox — a technical problem on our end, not yours. Here it is, several days late.
Most peptides we cover are short on human evidence. This week's is the opposite problem. Oxytocin has been in hospitals since the 1960s. It is on the WHO essential medicines list. Your hospital has some in a fridge right now.
And it is also sold as a nasal spray for connection, trust, and better relationships. Those two oxytocins share a molecule and almost nothing else.
Peptide 101: Oxytocin
Oxytocin is a nine-amino-acid neuropeptide (a very short protein your brain uses as a signal). Your hypothalamus makes it. Your posterior pituitary releases it.
You have probably heard it called the bonding or love hormone. Those nicknames are doing a lot of work, and most of the confusion around oxytocin starts there.
What is solidly established is mechanical. Oxytocin contracts the uterus during labor and triggers milk letdown during breastfeeding. The synthetic version, Pitocin, is FDA-approved for exactly two things: inducing labor, and managing postpartum hemorrhage. There are decades of obstetric use behind it.
What is not established is the part people buy sprays for. Intranasal oxytocin is still under investigation for autism, anxiety, and PTSD. Under investigation is the operative phrase.
How it works
Oxytocin is your body's social glue. It is released during moments of trust, closeness, and physical intimacy, and it reinforces those bonds by making social contact feel rewarding. At the same time it turns down your stress alarm, creating enough of a sense of safety for bonding to happen at all.
The technical version: oxytocin acts through oxytocin receptors (OXTRs) found both in the brain — the amygdala (the threat-detection center), hypothalamus, and hippocampus — and in peripheral tissue including the uterus, mammary glands, and heart. Centrally it modulates GABAergic and serotonergic signaling (two of the brain's main chemical messaging systems), reduces amygdala reactivity to threat, and heightens social salience, meaning social cues stand out more. Peripherally it contracts uterine smooth muscle and drives milk ejection. It also acts on the HPA axis (hypothalamic-pituitary-adrenal — the chain of glands that runs your stress response).
What the evidence shows
Our read on the overall strength of the evidence: Strong Evidence. That grade needs a caveat, and the caveat is the whole point of this issue.
The grade reflects the obstetric use. On labor induction and postpartum hemorrhage, oxytocin is about as well-evidenced as a drug gets. On the social and psychiatric claims, the picture is considerably thinner. Same molecule, very different footing.
What that rests on:
Intranasal oxytocin and social cognition, meta-analysis (2017) — Improved emotion recognition and social memory, with modest effect sizes.
Oxytocin in autism spectrum disorders (2017) — Mixed across trials. Some improvement in social reciprocity, but no consistent benefit on primary endpoints.
Oxytocin in CNS disorders, review (2026) — Described reported neuroprotective and antioxidant effects and possible application in neurodegenerative and neuropsychiatric conditions, while noting that dosing standardization remains unresolved.
That last unresolved point matters more than it sounds. Very little intranasal oxytocin reaches the brain, and researchers still disagree on how much, which means trials are not always comparing the same thing.
Note, preliminary or early findings are not the same as proof. Any use beyond a peptide's FDA-approved labeling (where one exists) is described here for educational purposes only and is not a recommendation.
Safety
The two delivery routes carry different risks, and they are worth separating.
Intravenous oxytocin (Pitocin), given in a hospital under monitoring, can cause uterine hyperstimulation, water intoxication and hyponatremia (dangerously low blood sodium, because oxytocin also makes you retain water), nausea, vomiting, and rarely cardiac arrhythmias.
Intranasal oxytocin is generally well tolerated. Reported side effects are nasal irritation, headache, and drowsiness.
Two less obvious concerns are worth knowing. There are questions about relying on exogenous oxytocin for social functioning. And the social effects are not uniformly warm: some studies report increased hostility toward out-groups, which is not what the bonding-hormone framing would lead you to expect.
Reasons to avoid it, or to talk to a clinician first:
Known hypersensitivity to oxytocin or any component
Pregnancy, except under specific obstetric protocols for labor induction
Cardiovascular disease, which may bring hypotension or arrhythmia at high doses
Hyponatremia, given oxytocin's water-retaining effects
This is not a complete safety list. It is the set of things worth knowing before a conversation with a prescriber.
Questions worth bringing to a clinician
Is intranasal oxytocin appropriate for my specific condition?
What is the current evidence for oxytocin in autism or social anxiety?
How might oxytocin interact with my psychiatric medications?
New research, translated
Two trials worth noting this week, both about how drugs behave outside the populations they were tested in.
Tirzepatide in Pakistan
ClinicalTrials.gov · tirzepatide · observational
A multicenter prospective study following tirzepatide in routine care in Pakistan. Tirzepatide is already approved for type 2 diabetes and obesity, but there is very little data on how it performs in South Asian populations and none from Pakistan specifically.
Worth watching. Most of what we know about GLP-1 drugs comes from trials run in North America and Europe, and that is a real limitation nobody advertises.
Switching from semaglutide to mazdutide in fatty liver disease
ClinicalTrials.gov · mazdutide · interventional
An investigator-initiated randomized trial testing what happens when patients with type 2 diabetes and moderate-to-severe non-alcoholic fatty liver disease, already at goal on semaglutide, switch to mazdutide.
The switching question is the useful part. Head-to-head data on what happens when you move someone between these drugs is scarce, and it is the question clinicians actually face.
What we're tracking
BPC-157 turning up in clinical notes. A new effort is curating patient-reported outcomes for unapproved BPC-157 — the "Wolverine peptide" — from real clinical records. Given how little completed human trial data exists, documenting what people are already doing is a reasonable place to start.
Semaglutide's brainstem circuitry, with new work mapping the specific pathways it uses to suppress feeding and shift energy expenditure.
Low-dose compounded semaglutide paired with behavioral weight management, in a real-world matched cohort.
About Oxytocin (this peptide)
Oxytocin (Pitocin) is an FDA-approved prescription medication indicated for: Labor induction; Postpartum hemorrhage. Any discussion of uses beyond the FDA-approved labeling is for educational purposes only and does not constitute a recommendation for off-label use. Oxytocin is a prescription medication that requires a valid prescription from a licensed healthcare provider. Do not attempt to obtain or use this medication without proper medical supervision.
Medical disclaimer
This letter is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and no provider-patient relationship is created by reading it. Peptides and medications discussed may not be FDA-approved for the uses described. Always consult your healthcare provider before making any health decision. Read our full medical disclaimer.